Royalty Pharma PLC (RPRX)
30.54
+0.10
(+0.31%)
USD |
NASDAQ |
Mar 28, 13:43
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 13.64B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -16.34% |
Valuation | |
PE Ratio | 12.12 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 7.819 |
Price to Book Value | 2.090 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 0.21 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.9401 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
Profile
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates. |
URL | https://www.royaltypharma.com |
Investor Relations URL | https://www.royaltypharma.com/investors |
HQ State/Province | New York |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Mid Cap/Value |
Next Earnings Release | May. 09, 2024 (est.) |
Last Earnings Release | Feb. 15, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Feb. 15, 2024 |
Ratings
Profile
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates. |
URL | https://www.royaltypharma.com |
Investor Relations URL | https://www.royaltypharma.com/investors |
HQ State/Province | New York |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Mid Cap/Value |
Next Earnings Release | May. 09, 2024 (est.) |
Last Earnings Release | Feb. 15, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Feb. 15, 2024 |